The antibody was purified by affinity chromatography, and conjugated with PE/Cy5 under optimal conditions. The solution is free of unconjugated PE/Cy5 and unconjugated antibody.
Storage & Handling:
The antibody solution should be stored undiluted at 4°C and protected from prolonged exposure to light. Do not freeze.
Application:
FC
Recommended Usage:
Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining, the suggested use of this reagent is 20 µl per 1 million cells or 20 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.
Human pre-B cell line REH stained with BV10A4H2 PE/Cy5
Description:
CD135 is a 130-160 type III tyrosine kinase receptor expressed on CD34+ hematopoietic stem cells, myelomonocytic progenitors, primitive B cell progenitors, and thymocytes. CD135 is also expressed on malignant hematopoietic cells including AML, ALL and CML-BC. CD135, also known as FMS-like tyrosine kinase-3, FLT3, STK-1, and Flk-2, is a growth factor receptor that binds the FLT3 ligand to promote the growth and differentiation of primitive hematopoietic cells. The intracytoplasmic domain of CD135 is modified by phosphorylation and has been shown to interact with Grb2, SOCS1, VAV1, and Shc.
Other Names:
FMS-like tyrosine kinase-3, FLT-3, STK-1, Flk-2
Structure:
Member of the immunoglobulin supergene family, type 3 tyrosine kinase receptor; 130-160 kD
Distribution:
Expressed on CD34+ hematopoietic stem cells, myelomonocytic progenitors, primitive B cell progenitors, and thymocytes. Also expressed on AML, ALL and CML-BC tumor cells
Function:
Tyrosine kinase growth factor receptor involved in the growth and differentiation of primitive hematopoietic cells
Ligand Receptor:
FLT3 ligand
Antigen References:
1. Rappold, I., et al. 1997. Blood 90:111. 2. Rosnet, O., et al. 1996. Acta Haematol. 95:218. 3. Rosnet, O., et al. 1996. Leukemia 10:238. 4. Bertho, J. M., et al. 2000. Scand. J. Immunol. 52:53.
